Vitamin D deficiency and outcome of COVID-19 patients

• Verfasst von: Radujković, Aleksandar [VerfasserIn]
• Verfasst von: Wenz, Theresa [VerfasserIn]
• Verfasst von: Tiwari-Heckler, Shilpa [VerfasserIn]
• Verfasst von: Dreher, Saida [VerfasserIn]
• Verfasst von: Boxberger, Monica [VerfasserIn]
• Verfasst von: Merle, Uta [VerfasserIn]
• Titel: Vitamin D deficiency and outcome of COVID-19 patients
• Verf.angabe: Aleksandar Radujkovic, Theresa Hippchen, Shilpa Tiwari-Heckler, Saida Dreher, Monica Boxberger and Uta Merle
• E-Jahr: 2020
• Jahr: 10 September 2020
• Umfang: 13 S.
• Fussnoten: Gesehen am 12.11.2020
• Titel Quelle: Enthalten in: Nutrients
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2020
• Band/Heft Quelle: 12(2020,9) Artikel-Nummer 2757, 13 Seiten
• ISSN Quelle: 2072-6643
• DOI: doi:10.3390/nu12092757
• Datenträger: Online-Ressource
• Sprache: eng
• Bibliogr. Hinweis: Ergänzung: Brenner, Hermann: Vitamin D insufficiency may account for almost nine of ten COVID-19 deaths
• Sach-SW: COVID-19
• Sach-SW: outcome
• Sach-SW: retrospective
• Sach-SW: SARS-CoV-2
• Sach-SW: severity
• Sach-SW: vitamin D
• K10plus-PPN: 1738571106

Abstract

Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses an enormous challenge to health care systems throughout the world. Without causal treatment, identification of modifiable prognostic factors may help to improve outcomes. To explore possible associations of vitamin D (VitD) status with disease severity and survival, we studied 185 patients diagnosed with coronavirus disease 2019 (COVID-19) and treated at our center. VitD status at first presentation was assessed retrospectively using accredited laboratory methods. VitD deficiency was defined as serum total 25-hydroxyvitamin D level < 12 ng/mL (<30 nM). Primary endpoint was severe course of disease (i.e., need for invasive mechanical ventilation and/or death, IMV/D). Within a median observation period of 66 days (range 2&ndash;92), 23 patients required IMV. A total of 28 patients had IMV/D, including 16 deaths. Ninety-three (50%) patients required hospitalization (inpatient subgroup). A total of 41 (22%) patients were VitD deficient. When adjusted for age, gender, and comorbidities, VitD deficiency was associated with higher risk of IMV/D and death (HR 6.12, 95% CI 2.79&ndash;13.42, p < 0.001 and HR 14.73, 95% CI 4.16&ndash;52.19, p < 0.001, respectively). Similar correlations were observed in the inpatient subgroup. Our study demonstrates an association between VitD deficiency and severity/mortality of COVID-19, highlighting the need for interventional studies on VitD supplementation in SARS-CoV-2 infected individuals.